154 results on '"Pane, Marco"'
Search Results
2. Cell-free Lactiplantibacillus plantarum OC01 supernatant suppresses IL-6-induced proliferation and invasion of human colorectal cancer cells: Effect on β-Catenin degradation and induction of autophagy
- Author
-
Vallino, Letizia, Garavaglia, Beatrice, Visciglia, Annalisa, Amoruso, Angela, Pane, Marco, Ferraresi, Alessandra, and Isidoro, Ciro
- Published
- 2023
- Full Text
- View/download PDF
3. An animal derivative-free medium enhances Lactobacillus johnsonii LJO02 supernatant selective efficacy against the methicillin (oxacillin)-resistant Staphylococcus aureus virulence through key-metabolites
- Author
-
Squarzanti, Diletta Francesca, Zanetta, Paola, Ormelli, Margherita, Manfredi, Marcello, Barberis, Elettra, Vanella, Virginia Vita, Amoruso, Angela, Pane, Marco, and Azzimonti, Barbara
- Published
- 2022
- Full Text
- View/download PDF
4. Facial Acne: A Randomized, Double-Blind, Placebo-Controlled Study on the Clinical Efficacy of a Symbiotic Dietary Supplement
- Author
-
Rinaldi, Fabio, Marotta, Laura, Mascolo, Antonio, Amoruso, Angela, Pane, Marco, Giuliani, Giammaria, and Pinto, Daniela
- Published
- 2022
- Full Text
- View/download PDF
5. Efficacy of Limosilactobacillus fermentum in the management of vulvovaginal candidiasis: comparative analysis with topical miconazole in a single-blind randomized clinical trial.
- Author
-
Pane, Marco and Chisari, Emanuele
- Subjects
VULVOVAGINAL candidiasis ,PATIENT compliance ,CLINICAL trials ,TREATMENT effectiveness ,MICONAZOLE - Abstract
Introduction: Vulvovaginal candidiasis (VVC) significantly impacts women's quality of life and often shows a high recurrence rate despite conventional antifungal therapies. This study evaluates the efficacy of Limosilactobacillus fermentum (LF5), a probiotic, as an alternative treatment option to conventional miconazole therapy in managing VVC. Methods: The randomized, single-blind clinical trial involved 100 premenopausal women diagnosed with VVC. Participants were assigned to either a vaginal capsule containing LF5 probiotic strain or miconazole. Treatments were administered once daily for three consecutive days. Microbiological eradication of Candida spp. and recurrence rates were assessed at 30 days post-treatment. The trial was registered with the Italian Ministry of Health. Results: Both treatments achieved a high rate of microbiological eradication of Candida spp. within the three-day treatment period (96% for LF5 and 94% for miconazole). Recurrence rates within 2 weeks post-treatment were low and similar between the groups (10% for LF5 and 17% for miconazole). LF5 was found to have a significantly lower incidence of local adverse reactions compared to miconazole (4 vs. 12%). Discussion: LF5 presents a viable alternative to miconazole for the treatment of VVC, offering comparable efficacy with fewer side effects. The results suggest that probiotic treatments can potentially enhance patient compliance and quality of life by reducing adverse reactions and recurrence rates. Further research is needed to confirm these findings in larger and more diverse populations. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Proof of concept: real-time viability and metabolic profiling of probiotics with isothermal microcalorimetry.
- Author
-
Morazzoni, Carlotta, Sirel, Madle, Allesina, Serena, Garcia, Marta Veses, Kragh, Kasper, Pane, Marco, and Beilharz, Katrin
- Subjects
PROBIOTICS ,MICROCALORIMETRY ,PROOF of concept ,BACTERIAL inactivation ,MICROBIAL growth ,INDUSTRIAL research - Abstract
Isothermal microcalorimetry (IMC) is a potent analytical method for the realtime assessment of microbial metabolic activity, which serves as an indicator of microbial viability. This approach is highly relevant to the fields of probiotics and Live Biotherapeutic Products (LBPs), offering insights into microbial viability and growth kinetics. One important characteristic of IMC is its ability to measure microbial metabolic activity separately from cellular enumeration. This is particularly useful in situations where continuous tracking of bacterial activity is challenging. The focus on metabolic activity significantly benefits both probiotic research and industrial microbiology applications. IMC's versatility in handling different media matrices allows for the implementation of viability assessments under conditions that mirror those found in various industrial environments or biological models. In our study, we provide a proof of concept for the application of IMC in determining viability and growth dynamics and their correlation with bacterial count in probiotic organisms. Our findings reinforce the potential of IMC as a key method for process enhancement and accurate strain characterization within the probiotic sector. This supports the broader objective of refining the systematic approach and methods used during the development process, thereby providing detailed insights into probiotics and LBPs. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Bifidobacterium longum W11: Uniqueness and individual or combined clinical use in association with rifaximin
- Author
-
Di Pierro, Francesco and Pane, Marco
- Published
- 2021
- Full Text
- View/download PDF
8. Intestinal microbiome: a new target for chalaziosis treatment in children?
- Author
-
Filippelli, Mariaelena, dell’Omo, Roberto, Amoruso, Angela, Paiano, Ilaria, Pane, Marco, Napolitano, Pasquale, Bartollino, Silvia, and Costagliola, Ciro
- Published
- 2021
- Full Text
- View/download PDF
9. Probiotics-addicted low-protein diet for microbiota modulation in patients with advanced chronic kidney disease (ProLowCKD): A protocol of placebo-controlled randomized trial
- Author
-
De Mauri, Andreana, Carrera, Deborah, Bagnati, Marco, Rolla, Roberta, Chiarinotti, Doriana, Mogna, Luca, Pane, Marco, Amoruso, Angela, and Del Piano, Mario
- Published
- 2020
- Full Text
- View/download PDF
10. Innovative Biomarkers for Obesity and Type 1 Diabetes Based on Bifidobacterium and Metabolomic Profiling.
- Author
-
Nobili, Angelica, Pane, Marco, Skvortsova, Mariya, Ben Salem, Meryam, Morgenthaler, Stephan, Jamieson, Emily, Di Stefano, Marina, Bathrellou, Eirini, Mamalaki, Eirini, Ramos-Garcia, Victoria, Kuligowski, Julia, Vasileiadis, Miltiadis, Georgiadis, Panagiotis, Falcone, Marika, and Refinetti, Paulo
- Subjects
TYPE 1 diabetes ,MICROBIAL metabolites ,BIFIDOBACTERIUM ,SHORT-chain fatty acids ,BIFIDOBACTERIUM bifidum ,OVERWEIGHT children - Abstract
The role of Bifidobacterium species and microbial metabolites such as short-chain fatty acids (SCFAs) and human milk oligosaccharides in controlling intestinal inflammation and the pathogenesis of obesity and type 1 diabetes (T1D) has been largely studied in recent years. This paper discusses the discovery of signature biomarkers for obesity and T1D based on data from a novel test for profiling several Bifidobacterium species, combined with metabolomic analysis. Through the NUTRISHIELD clinical study, a total of 98 children were recruited: 40 healthy controls, 40 type 1 diabetics, and 18 obese children. Bifidobacterium profiles were assessed in stool samples through an innovative test allowing high taxonomic resolution and precise quantification, while SCFAs and branched amino acids were measured in urine samples through gas chromatography–mass spectrometry (GC-MS). KIDMED questionnaires were used to evaluate the children's dietary habits and correlate them with the Bifidobacterium and metabolomic profiles. We found that B. longum subs. infantis and B. breve were higher in individuals with obesity, while B. bifidum and B. longum subs. longum were lower compared to healthy individuals. In individuals with T1D, alterations were found at the metabolic level, with an overall increase in the level of the most measured metabolites. The high taxonomic resolution of the Bifidobacterium test used meant strong correlations between the concentrations of valine and isoleucine, and the relative abundance of some Bifidobacterium species such as B. longum subs. infantis, B. breve, and B. bifidum could be observed. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Lactobacillus johnsonii LJO02 (DSM 33828) Cell-Free Supernatant and Vitamin D Improve Wound Healing and Reduce Interleukin-6 Production in Staphylococcus aureus -Infected Human Keratinocytes.
- Author
-
Zanetta, Paola, Ballacchino, Chiara, Squarzanti, Diletta Francesca, Amoruso, Angela, Pane, Marco, and Azzimonti, Barbara
- Subjects
WOUND healing ,STAPHYLOCOCCUS aureus ,MULTIDRUG resistance in bacteria ,MICROCOCCACEAE ,INTERLEUKIN-6 ,KERATINOCYTES ,VITAMIN D ,LACTOBACILLUS - Abstract
Methicillin-resistant biofilm-forming Staphylococcus spp. are found in about 25% of the overall cases of chronic wounds, which can undergo malignant degeneration and be associated with skin cancer. Although antimicrobial agents are clinically used to counteract pathogens and promote wound healing, they are increasingly ineffective against multi-drug resistant bacteria. Moreover, they can induce dysbiosis, which favors opportunistic pathogen infections and alters immune responses. Consequently, research on pathogen containment strategies is crucial. We aimed to evaluate the potential beneficial effect of Lactobacillus johnsonii LJO02 cell-free supernatant (CFS) and vitamin D, as single treatments or in combination, on cell viability, wound healing, and the pro-inflammatory interleukin-6 (IL-6) production of a Staphylococcus aureus-infected human immortalized keratinocyte cell line (HaCaT) in vitro model. The analysis showed that LJO02 CFS 20% v/v ratio and 100 nM vitamin D promoted infected cell viability and wound healing and significantly reduced IL-6 production. However, their effect was not synergic, since no significant difference between the single and combined treatments was observed. LJO02 CFS topic application and vitamin D supplementation could provide a valuable strategy for attenuating S. aureus-induced pathogenesis, promoting wound healing and opening new therapeutic strategies supporting the conventional approaches. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. A randomized controlled trial to examine the impact of a multi-strain probiotic on self-reported indicators of depression, anxiety, mood, and associated biomarkers.
- Author
-
Walden, Kylie E., Moon, Jessica M., Hagele, Anthony M., Allen, Leah E., Gaige, Connor J., Krieger, Joesi M., Jäger, Ralf, Mumford, Petey W., Pane, Marco, and Kerksick, Chad M.
- Published
- 2023
- Full Text
- View/download PDF
13. Exploring the Effects of Probiotic Treatment on Urinary and Serum Metabolic Profiles in Healthy Individuals.
- Author
-
Di Cesare, Francesca, Calgaro, Matteo, Ghini, Veronica, Squarzanti, Diletta Francesca, De Prisco, Annachiara, Visciglia, Annalisa, Zanetta, Paola, Rolla, Roberta, Savoia, Paola, Amoruso, Angela, Azzimonti, Barbara, Vitulo, Nicola, Tenori, Leonardo, Luchinat, Claudio, and Pane, Marco
- Published
- 2023
- Full Text
- View/download PDF
14. Probiotics and Prebiotics Orally Assumed as Disease Modifiers for Stable Mild Atopic Dermatitis: An Italian Real-Life, Multicenter, Retrospective, Observational Study.
- Author
-
Colombo, Delia, Rigoni, Corinna, Cantù, Alessandra, Carnevali, Antonello, Filippetti, Rossella, Franco, Tiziana, Grassi, Alessandra, Loi, Camilla, Mazzotta, Annamaria, Patroi, Ivona, Raone, Beatrice, Tomassini, Marco Andrea, Amoruso, Angela, Pane, Marco, and Damiani, Giovanni
- Subjects
ATOPIC dermatitis ,PROBIOTICS ,PREBIOTICS ,SCIENTIFIC observation ,BIFIDOBACTERIUM ,ITCHING ,ROSACEA - Abstract
The role of the skin–gut axis in atopic dermatitis (AD) remains a subject of debate, limiting non-pharmacological interventions such as probiotics and prebiotics. To improve understanding of their potential as a monotherapy for stable mild cases, we conducted a real-life, multicenter, retrospective observational study in Italy. We administered three selected bacteria (Bifidobacterium animalis subsp. lactis BS01, Lactiplantibacillus plantarum LP14, and Lacticaseibacillus rhamnosus LR05) orally to patients with mild atopic dermatitis without a placebo control group, following up for 12 weeks. Clinical assessments using the Scoring Atopic Dermatitis (SCORAD), Eczema Area and Severity Index (EASI), and Three-Item Severity (TIS) score were conducted on 144 enrolled patients (average age: 25.1 ± 17.6 years). Notably, both pruritus and AD-related lesions (erythema, edema/papules, excoriation) exhibited significant clinical and statistical improvement (p < 0.001) after 12 weeks of exclusive probiotic and prebiotic use. These preliminary results suggest a potential link between the skin–gut microbiome and support the rationale for using specific probiotics and prebiotics in mild AD, even for maintenance, to reduce flares and dysbiosis. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
15. A prospective longitudinal study on the microbiota composition in amyotrophic lateral sclerosis
- Author
-
Di Gioia, Diana, Bozzi Cionci, Nicole, Baffoni, Loredana, Amoruso, Angela, Pane, Marco, Mogna, Luca, Gaggìa, Francesca, Lucenti, Maria Ausiliatrice, Bersano, Enrica, Cantello, Roberto, De Marchi, Fabiola, and Mazzini, Letizia
- Published
- 2020
- Full Text
- View/download PDF
16. The athletic gut microbiota
- Author
-
Mohr, Alex E., Jäger, Ralf, Carpenter, Katie C., Kerksick, Chad M., Purpura, Martin, Townsend, Jeremy R., West, Nicholas P., Black, Katherine, Gleeson, Michael, Pyne, David B., Wells, Shawn D., Arent, Shawn M., Kreider, Richard B., Campbell, Bill I., Bannock, Laurent, Scheiman, Jonathan, Wissent, Craig J., Pane, Marco, Kalman, Douglas S., Pugh, Jamie N., Ortega-Santos, Carmen P., ter Haar, Jessica A., Arciero, Paul J., and Antonio, Jose
- Published
- 2020
- Full Text
- View/download PDF
17. International Society of Sports Nutrition Position Stand: Probiotics
- Author
-
Jäger, Ralf, Mohr, Alex E., Carpenter, Katie C., Kerksick, Chad M., Purpura, Martin, Moussa, Adel, Townsend, Jeremy R., Lamprecht, Manfred, West, Nicholas P., Black, Katherine, Gleeson, Michael, Pyne, David B., Wells, Shawn D., Arent, Shawn M., Smith-Ryan, Abbie E., Kreider, Richard B., Campbell, Bill I., Bannock, Laurent, Scheiman, Jonathan, Wissent, Craig J., Pane, Marco, Kalman, Douglas S., Pugh, Jamie N., ter Haar, Jessica A., and Antonio, Jose
- Published
- 2019
- Full Text
- View/download PDF
18. Collaborative cytometric inter-laboratory ring test for probiotics quantification.
- Author
-
Jordal, Peter Lüttge, Diaz, Marcos González, Morazzoni, Carlotta, Allesina, Serena, Zogno, Daniele, Cattivelli, Daniela, Galletti, Serena, Guidesi, Elena, Warzée, Jean-Pol, and Pane, Marco
- Subjects
PROBIOTICS ,FLOW cytometry ,BACTERIAL cells ,BACTERIAL inactivation ,BIFIDOBACTERIUM ,FLUOROPHORES - Abstract
Introduction: Probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit on the host. From this definition, accurate enumeration of probiotic products is a necessity. Nonetheless, this definition does not specify the methods for assessing such viability. Colony forming units is the de facto gold standard for enumerating viable in probiotic products. The notion of microbial viability has been anchored in the concept of cultivability, which refers to a cell's capacity to replicate and form colonies on agar media. However, there is a growing consensus that the term "viability" should not be exclusively tied to the ability to cultivate cells. For example, bacterial cells can exist in a Viable But Non-Culturable (VBNC) state, characterized by the maintenance of characteristics such as membrane integrity, enzymatic activity, pH gradients, and elevated levels of rRNA, despite losing the ability to form colonies. Methods: Herein we present the results of a collaborative inter-laboratory ring test for cytometric bacterial quantification. Specifically, membrane integrity fluorescence flow cytometry (FFC) method and the newer impedance flow cytometry (IFC) method have been used. Both methods interrogate single cells in solution for the presence of intact membranes. FFC exploits fluorochromes that reflect the presence or absence of an intact membrane. IFC probes membrane integrity in a label-free approach by detecting membrane-induced hindrances to the propagation of electricity. Results: A performance ring-test and comparison design on the FFC method showed that the method is robust against the exchange of equipment, procedures, materials, and operators. After initial method optimization with assessments of rehydration medium, wake-up duration, and phase shift gating on the individual strains, the IFC method showed good agreement with the FFC results. Specifically, we tested 6 distinct species of probiotic bacteria (3 Lactobacillus and 3 Bifidobacterium strains) finding good agreement between FFC and IFC results in terms of total and live cells. Discussion: Together, these results demonstrate that flow cytometry is a reliable, precise, and user-friendly culture-independent method for bacterial enumeration. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
19. Beneficial Effects of Lactobacilli Species on Intestinal Homeostasis in Low-Grade Inflammation and Stress Rodent Models and Their Implication in the Modulation of the Adhesive Junctional Complex.
- Author
-
Chamignon, Célia, Mallaret, Geoffroy, Rivière, Julie, Vilotte, Marthe, Chadi, Sead, de Moreno de LeBlanc, Alejandra, LeBlanc, Jean Guy, Carvalho, Frédéric Antonio, Pane, Marco, Mousset, Pierre-Yves, Langella, Philippe, Lafay, Sophie, and Bermúdez-Humarán, Luis G.
- Subjects
MUCUS ,HOMEOSTASIS ,INTESTINES ,CHEMICAL reactions ,GUT microbiome ,ADHESIVES ,CLAUDINS - Abstract
Intestinal barrier integrity is essential in order to maintain the homeostasis of mucosal functions and efficient defensive reactions against chemical and microbial challenges. An impairment of the intestinal barrier has been observed in several chronic diseases. The gut microbiota and its impact on intestinal homeostasis is well described and numerous studies suggest the ability of some probiotic strains to protect the intestinal epithelial integrity and host homeostasis. In this work, we aimed to assess the beneficial effects of three Lactobacillus strains (Lacticaseibacillus rhamnosus LR04, Lacticaseibacillus casei LC03, and Lactiplantibacillus plantarum CNCM I-4459) and their mechanism of action in low-grade inflammation or neonatal maternal separation models in mice. We compared the impact of these strains to that of the well-known probiotic Lacticaseibacillus rhamnosus GG. Our results demonstrated that the three strains have the potential to restore the barrier functions by (i) increasing mucus production, (ii) restoring normal permeability, and (iii) modulating colonic hypersensitivity. Moreover, gene expression analysis of junctional proteins revealed the implication of Claudin 2 and Cingulin in the mechanisms that underlie the interactions between the strains and the host. Taken together, our data suggest that LR04, CNCM I-4459, and LC03 restore the functions of an impaired intestinal barrier. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
20. New Approach in Acne Therapy: A Specific Bacteriocin Activity and a Targeted Anti IL-8 Property in Just 1 Probiotic Strain, the L. salivarius LS03
- Author
-
Deidda, Francesca, Amoruso, Angela, Nicola, Stefania, Graziano, Teresa, Pane, Marco, and Mogna, Luca
- Published
- 2018
- Full Text
- View/download PDF
21. Potential Role of Gut Microbiota in ALS Pathogenesis and Possible Novel Therapeutic Strategies
- Author
-
Mazzini, Letizia, Mogna, Luca, De Marchi, Fabiola, Amoruso, Angela, Pane, Marco, Aloisio, Irene, Cionci, Nicole Bozzi, Gaggìa, Francesca, Lucenti, Ausiliatrice, Bersano, Enrica, Cantello, Roberto, Di Gioia, Diana, and Mogna, Giovanni
- Published
- 2018
- Full Text
- View/download PDF
22. Flow Cytometry: Evolution of Microbiological Methods for Probiotics Enumeration
- Author
-
Pane, Marco, Allesina, Serena, Amoruso, Angela, Nicola, Stefania, Deidda, Francesca, and Mogna, Luca
- Published
- 2018
- Full Text
- View/download PDF
23. Gut Microbiota, Probiotics, and Sport: From Clinical Evidence to Agonistic Performance
- Author
-
Pane, Marco, Amoruso, Angela, Deidda, Francesca, Graziano, Teresa, Allesina, Serena, and Mogna, Luca
- Published
- 2018
- Full Text
- View/download PDF
24. Micronized Cells of the Probiotic Strain Bifidobacterium lactis BS01 Activate Monocyte Polarization: A New Approach
- Author
-
Mogna, Luca, Amoruso, Angela, Pane, Marco, Nicola, Stefania, Allesina, Serena, and Deidda, Francesca
- Published
- 2018
- Full Text
- View/download PDF
25. Growth Conditions Influence Lactobacillus Cell-Free Supernatant Impact on Viability, Biofilm Formation, and Co-Aggregation of the Oral Periodontopathogens Fusobacterium nucleatum and Porphyromonas gingivalis.
- Author
-
Zanetta, Paola, Squarzanti, Diletta Francesca, di Coste, Alessia, Amoruso, Angela, Pane, Marco, and Azzimonti, Barbara
- Subjects
PORPHYROMONAS gingivalis ,FUSOBACTERIUM ,LACTOBACILLUS ,SQUAMOUS cell carcinoma ,BIOFILMS - Abstract
Fusobacterium nucleatum and Porphyromonas gingivalis human periodontopathogens play a leading part in oral squamous cell carcinoma through cell proliferation, invasion, and persistent inflammation promotion and maintenance. To explore how the activity of Lactobacillus-derived cell-free supernatants (CFSs) can be influenced by growth medium components, CFSs were produced both in the standard MRS and the novel animal-derivative-free "Terreno Industriale Lattobacilli" (TIL) media, and in vitro screened for the containment of F. nucleatum and P. gingivalis both single and co-cultured and also for the interference on their co-aggregation. The viability assay demonstrated that the Limosilactobacillus reuteri LRE11 and Ligilactobacillus salivarius LS03 MRS-produced CFSs were significantly more effective against single and co-cultured pathogens. All the other CFSs significantly improved their efficacy when produced in TIL. Both MRS- and TIL-produced CFSs significantly inhibited the single and co-cultured pathogen biofilm formation. Only Levilactobacillus brevis LBR01 CFS in MRS specifically reduced F. nucleatum and P. gingivalis co-aggregation, while viable LBR01, LS03, and LRE11 in MRS significantly co-aggregated with the pathogens, but only LS03 cultivated in TIL improved this effect. This work paves the way to better consider environmental growth conditions when screening for probiotic and postbiotic efficacy as crucial to pathogen aggregation, adhesion to the host's niches, and exclusion. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
26. The Probiotics in Pediatric Asthma Management (PROPAM) study: A Post Hoc analysis in allergic children
- Author
-
Ciprandi, Giorgio, Schiavetti, Irene, Cioffi, Luigi, Pane, Marco, and Drago, Lorenzo
- Published
- 2022
- Full Text
- View/download PDF
27. 732 EFFECTS OF PROBIOTIC MIXTURE STANDARDIZED WITH MALTODEXTRIN ON COLONIC DYSMOTILITY AND ENTERIC INFLAMMATION IN A SPONTANEOUS MODEL OF ACCELERATE SENESCENCE
- Author
-
Pierucci, Clarissa, Benvenuti, Laura, Visciglia, Annalisa, Segnani, Cristina, Ippolito, Chiara, D'Antongiovanni, Vanessa, Salvo, Clelia Di, Valdiserra, Giulia, Colucci, Rocchina, Amoruso, Angela, Pane, Marco, Fornai, Matteo, Antonioli, Luca, Bernardini, Nunzia, and Pellegrini, Carolina
- Published
- 2024
- Full Text
- View/download PDF
28. In Vitro Selection of Lactobacillus and Bifidobacterium Probiotic Strains for the Management of Oral Pathobiont Infections Associated to Systemic Diseases.
- Author
-
Zanetta, Paola, Squarzanti, Diletta Francesca, di Coste, Alessia, Rolla, Roberta, Valletti, Paolo Aluffi, Garzaro, Massimiliano, Dell'Era, Valeria, Amoruso, Angela, Pane, Marco, and Azzimonti, Barbara
- Subjects
BIFIDOBACTERIUM ,PROBIOTICS ,LACTOBACILLUS ,ACTINOBACILLUS actinomycetemcomitans ,STREPTOCOCCUS mutans ,MULTIDRUG resistance - Abstract
The human oral pathobionts Aggregatibacter actinomycetemcomitans, Streptococcus mitis and Streptococcus mutans, in dysbiosis-promoting conditions, lead to oral infections, which also represent a threat to human systemic health. This scenario may be worsened by antibiotic misuse, which favours multi-drug resistance, making the research on pathogen containment strategies more than crucial. Therefore, we aimed to in vitro select the most promising probiotic strains against oral pathogen growth, viability, biofilm formation, and co-aggregation capacity, employing both the viable probiotics and their cell-free supernatants (CFSs). Interestingly, we also assessed probiotic efficacy against the three-pathogen co-culture, mimicking an environment similar to that in vivo. Overall, the results showed that Lactobacillus CFSs performed better than the Bifidobacterium, highlighting Limosilactobacillus reuteri LRE11, Lacticaseibacillus rhamnosus LR04, Lacticaseibacillus casei LC04, and Limosilactobacillus fermentum LF26 as the most effective strains, opening the chance to deeper investigation of their action and CFS composition. Altogether, the methodologies presented in this study can be used for probiotic efficacy screenings, in order to better focus the research on a viable probiotic, or on its postbiotics, suitable in case of infections. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
29. In-process real-time probiotic phenotypic strain identity tracking: The use of Fourier transform infrared spectroscopy.
- Author
-
Deidda, Francesca, Cordovana, Miriam, Cionci, Nicole Bozzi, Graziano, Teresa, Di Gioia, Diana, and Pane, Marco
- Abstract
Probiotic bacteria, capable of conferring benefits to the host, can present challenges in design, development, scale-up, manufacturing, commercialization, and life cycle management. Strain identification is one of the main quality parameters; nevertheless, this task can be challenging since established methodologies can lack resolution at the strain level for some microorganisms and\or are labor-intensive and time-consuming. Fourier transform infrared spectroscopy (FTIRS) has been largely used for the investigation of pathogenic species in the clinical field, whereas only recently has been proposed for the identification of probiotic strains. Within the probiotic industrial production, bacterial strains can be subjected to stressful conditions that may affect genomic and phenotypic characteristics; therefore, real-time monitoring of all the sequential growth steps is requested. Considering the fast, low-cost, and high-throughput features, FTIRS is an innovative and functional technology for typing probiotic strains from benchtop experiments to large-scale industrial production, allowing the monitoring of stability and identity of probiotic strains. In this study, the discriminatory power of FTIRS was assessed for four Lactiplantibacillus plantarum probiotic strains grown under different conditions, including temperatures (30 and 37◦C) and medium (broth and agar), after consecutive sub-culturing steps. A comparison between the generated spectra with pulsed-field gel electrophoresis (PFGE) profiles was also performed. FTIRS was not only able to distinguish the strains of L. plantarum under different growth conditions but also to prove the phenotypic stability of L. plantarum type strain LP-CT after six growing steps. Regardless of the growth conditions, FTIRS spectra related to LP-CT constituted a unique hierarchical cluster, separated from the other L. plantarum strains. These results were confirmed by a PFGE analysis. In addition, based on FTIRS data, broth cultures demonstrated a higher reproducibility and discriminatory power with respect to agar ones. These results support the introduction of FTIRS in the probiotic industry, allowing for the step-by-step monitoring of massive microbial production while also guaranteeing the stability and purity of the probiotic strain. The proposed novel approach can constitute an impressive improvement in the probiotic manufacturing process. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
30. Assessment of shelf-life and metabolic viability of a multi-strain synbiotic using standard and innovative enumeration technologies.
- Author
-
Visciglia, Annalisa, Allesina, Serena, Amoruso, Angela, De Prisco, Annachiara, Dhir, Raja, Bron, Peter A., and Pane, Marco
- Abstract
The number of live bacterial cells is the most used parameter to assess the quality of finished probiotic products. Plate counting (PC) is the standard method in industry to enumerate cells. Application of PC implies critical aspects related to the selection of optimal nutrient media and growth conditions and underestimation of viable but not cultivable (VBNC) cells. Flow-cytometry (FC) is a culture-independent methodology having the potential to selectively enumerate live, damaged, and dead cells representing a powerful tool for in-depth monitoring of probiotic products. We monitored the shelf life of a clinical batch of a synbiotic composition PDS-08 targeting the pediatric population by means of PC and FC according to International Conference on Harmonization (ICH) pharma guidelines testing the Arrhenius model as predictive tool; PC enumeration revealed higher destruction rate than FC suggesting a faster reduction in cultivability than membrane integrity and thus a possible shift of the bacteria into a VBNC status. PDS-08 maintained acidification capability over time, when re-suspended in nutrient medium, even in samples tested sub-optimally for CFU detection (below 1 billion cells/dose). Due to similar kinetics described by the study of metabolic activity and membrane integrity, FC might be suggested as a valid tool for the study of functional stability of a probiotic product. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
31. The Gut-Ex-Vivo System (GEVS) Is a Dynamic and Versatile Tool for the Study of DNBS-Induced IBD in BALB/C and C57BL/6 Mice, Highlighting the Protective Role of Probiotics.
- Author
-
Monzani, Romina, Gagliardi, Mara, Clemente, Nausicaa, Saverio, Valentina, Pańczyszyn, Elżbieta, Santoro, Claudio, Yissachar, Nissan, Visciglia, Annalisa, Pane, Marco, Amoruso, Angela, and Corazzari, Marco
- Subjects
LABORATORY mice ,PROBIOTICS ,GUT microbiome ,BIFIDOBACTERIUM ,LACTOBACILLUS ,DISEASE progression ,GENE expression ,CELL death - Abstract
Simple Summary: IBD is considered a modern and western diet-related disease characterized by uncontrolled immune activation, resulting in chronic bowel inflammation and tissue damage. Although the precise causes of the onset of the disease are still elusive, it seems that both the environment, genetic predisposition and the dysregulation of the intestinal microbiota are actively involved. The development of a model to study the etiopathology of this disease characterized by an increasing incidence in the population is urgently needed. We have recently developed an organ-on-chip system (Gut-Ex-Vivo System, GEVS) to model IBD induced by DNBS in the colon of mice of the BALB/c strain. Here, we provide data demonstrating that the process can also be efficiently induced in mice of another strain, C57BL/6, which is usually less sensitive to this treatment, using our GEVS. Furthermore, we have shown that the system also replicates other characteristics of human pathology, such as the induction of the two most represented cell death pathways responsible for the tissue damage characteristic of IBD. Finally, we demonstrate that our system can be used efficiently to test new therapeutic interventions, such as those based on the use of probiotics. Indeed, we demonstrated the positive impact of both Lactobacilli and Bifidobacteria. Background: IBD is a spectrum of pathologies characterized by dysregulated immune activation leading to uncontrolled response against the intestine, thus resulting in chronic gut inflammation and tissue damage. Due to its complexity, the molecular mechanisms responsible for disease onset and progression are still elusive, thus requiring intense research effort. In this context, the development of models replicating the etiopathology of IBD and allowing the testing of new potential therapies is critical. Methods: Colon from C57BL/6 or BALB/c mice was cultivated in a Gut-Ex-Vivo System (GEVS), exposed for 5 h to DNBS 1.5 or 2.5 mg/mL, in presence or absence of two probiotic formulations (P1 = Bifidobacterium breve BR03 (DSM16604) and B632 (DSM24706); P2 = Lacticaseibacillus rhamnosus LR04 (DSM16605), Lactiplantibacillus plantarum LP14 (DSM33401) and Lacticaseibacillus paracasei LPC09), and the main hallmarks of IBD were evaluated. Results: Gene expression analysis revealed the following DNBS-induced effects: (i) compromised tight junction organization, responsible for tissue permeability dysregulation; (ii) induction of ER stress, and (iii) tissue inflammation in colon of C57BL/6 mice. Moreover, the concomitant DNBS-induced apoptosis and ferroptosis pathways were evident in colon from both BALB/c and C57BL/6 mice. Finally, the co-administration of probiotics completely prevented the detrimental effects of DNBS. Conclusions: Overall, we have provided results demonstrating that GEVS is a consistent, reliable, and cost-effective system for modeling DNBS-induced IBD, useful for studying the onset and progression of human disease at the molecular level, while also reducing animal suffering. Moreover, we have confirmed the beneficial effect of probiotics administration in promoting the remission of IBD. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
32. Randomized Double-Blind Crossover Study for Evaluating a Probiotic Mixture on Gastrointestinal and Behavioral Symptoms of Autistic Children.
- Author
-
Guidetti, Cristina, Salvini, Elena, Viri, Maurizio, Deidda, Francesca, Amoruso, Angela, Visciglia, Annalisa, Drago, Lorenzo, Calgaro, Matteo, Vitulo, Nicola, Pane, Marco, and Caucino, Anna Claudia
- Subjects
AUTISTIC children ,PARENTING Stress Index ,PERCEIVED Stress Scale ,AUTISM spectrum disorders ,GUT microbiome ,FECAL microbiota transplantation ,BEHAVIORAL assessment ,IRRITABLE colon - Abstract
Autism spectrum disorders (ASDs) represent a diagnostic challenge with a still partially uncertain etiology, in which genetic and environmental factors have now been assessed. Among the hypotheses underlying the involvement of biological and environmental factors, the gut–brain axis is of particular interest in autism spectrum disorders. Several studies have highlighted the related incidence of particular gastrointestinal symptoms (GISs) in children suffering from ASDs. Probiotics have shown success in treating several gastrointestinal dysbiotic disorders; therefore, it is plausible to investigate whether they can alleviate behavioral symptoms as well. On these bases, a randomized double-blind crossover study with a placebo was conducted, evaluating the effects of a mixture of probiotics in a group of 61 subjects aged between 24 months and 16 years old with a diagnosis of ASD. Behavioral evaluation was performed through the administration of a questionnaire including a Parenting Stress Index (PSI) test and the Vineland Adaptive Behavior Scale (VABS). The Psycho-Educational Profile and the Autism Spectrum Rating Scale (ASRS) were also evaluated. Microbial composition analyses of fecal samples of the two groups was also performed. The study showed significant improvements in GISs, communication skills, maladaptive behaviors, and perceived parental stress level after the administration of probiotics. Microbiome alpha diversity was comparable between treatment arms and no significant differences were found, although beta diversity results were significantly different in the treatment group between T0 and T1 time points. Streptococcus thermophilus, Bifidobacterium longum, Limosilactobacillus fermentum, and Ligilactobacillus salivarius species were identified as some of the most discriminant taxa positively associated with T1 samples. This preliminary study corroborates the relationship between intestinal microbiota and ASD recently described in the literature. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
33. Probiotics-Supplemented Low-Protein Diet for Microbiota Modulation in Patients with Advanced Chronic Kidney Disease (ProLowCKD): Results from a Placebo-Controlled Randomized Trial.
- Author
-
De Mauri, Andreana, Carrera, Deborah, Bagnati, Marco, Rolla, Roberta, Vidali, Matteo, Chiarinotti, Doriana, Pane, Marco, Amoruso, Angela, and Del Piano, Mario
- Abstract
The probiotics-supplemented low-protein diet in chronic kidney disease (ProLowCKD) was a single-centre, double-blind, placebo-controlled, randomised trial that was conducted to investigate whether the association between a low protein diet (LPD) and a new formulation of probiotics (Bifidobacterium longum and Lactobacillus reuteri) was effective at reducing traditional uremic, microbiota-derived, and proatherogenic toxins in sixty patients affected by advanced CKD. After 2 months of a LPD—a reduction in blood urea nitrogen (52 ± 17 vs. 46 ± 15 mg/dL, p = 0.003), total cholesterol (185 ± 41 vs. 171 ± 34 mg/dL, p = 0.001), and triglycerides (194 ± 148 vs. 161 ± 70 mg/dL, p = 0.03) was observed; 57 subjects were then randomized to receive probiotics or a placebo for the subsequent 3 months. A total of 27 patients in the placebo group showed increased serum values of total cholesterol (169 ± 36 vs. 185 ± 40 mg/dL, p = 0.01), LDL cholesterol (169 ± 36 vs. 185 ± 40 mg/dL, p = 0.02), lipoprotein-associated phospholipase A
2 (155.4 ± 39.3 vs. 167.5 ± 51.4 nmol/mL/min, p = 0.006), and indoxyl-sulphate (30.1 ± 17.6 vs. 34.5 ± 20.2 μM, p = 0.026), while the 24 subjects in the probiotics group showed a trend in the reduction of microbiota toxins. A reduction of antihypertensive and diuretic medications was possible in the probiotics group. This study shows that associating probiotics to LPD may have an additional beneficial effect on the control and modulation of microbiota-derived and proatherogenic toxins in CKD patients. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
34. Probiotics as Potential Biological Immunomodulators in the Management of Oral Lichen Planus: What's New?
- Author
-
Zanetta, Paola, Ormelli, Margherita, Amoruso, Angela, Pane, Marco, Azzimonti, Barbara, and Squarzanti, Diletta Francesca
- Subjects
PROBIOTICS ,ORAL lichen planus ,IMMUNOMODULATORS ,NF-kappa B ,HUMAN microbiota ,T cells - Abstract
Oral lichen planus (OLP) is a T cell-mediated chronic inflammatory disorder with multifactorial aetiology and malignant transformation potential. Despite the treatments so far identified, new tailored and safe specific measures are needed. Recently, human microbiota imbalance has been linked to several immune-mediated diseases, opening new therapeutic perspectives for probiotics; besides their ability to directly interact with the host microbiota, they also display a strain-specific immune-modulatory effect. Thus, this non-systematic review aims to elucidate the molecular pathways underlying probiotic activity, mainly those of Lactobacilli and Bifidobacteria and their metabolites in OLP pathogenesis and malignant transformation, focusing on the most recent in vitro and in vivo research evidence. Findings related to their activity in other immune-mediated diseases are here included, suggesting a probiotic translational use in OLP. Probiotics show immune-modulatory and microbiota-balancing activities; they protect the host from pathogens, hamper an excessive effector T cell response, reduce nuclear factor-kappa B (NF-kB) signalling and basal keratinocytes abnormal apoptosis, shifting the mucosal response towards the production of anti-inflammatory cytokines, thus preventing uncontrolled damage. Therefore, probiotics could be a highly encouraging prevention and immunotherapeutic approach for a safer and more sustainable OLP management. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
35. The Probiotics in Pediatric Asthma Management (PROPAM) Study in the Primary Care Setting: A Randomized, Controlled, Double-Blind Trial with LS01 (DSM 22775) and B632 (DSM 24706).
- Author
-
Drago, Lorenzo, Cioffi, Luigi, Giuliano, Maria, Pane, Marco, Amoruso, Angela, Schiavetti, Irene, Reid, Gregor, Ciprandi, Giorgio, and PROPAM Study Group
- Subjects
BIFIDOBACTERIUM ,PRIMARY care ,PROBIOTICS ,ASTHMA in children ,ASTHMA ,ASTHMA treatment ,PATHOGENESIS ,TREATMENT effectiveness ,PRIMARY health care ,RANDOMIZED controlled trials ,BLIND experiment ,STATISTICAL sampling - Abstract
Background: Type-2 inflammation commonly marks asthma in childhood. Also, gut and lung dysbiosis is detectable in patients with asthma. Strain-related probiotic supplementation may restore a physiological immune response, dampen airway inflammation, and repair dysbiosis. Therefore, the probiotics in pediatric asthma management (PROPAM) study is aimed at demonstrating that Ligilactobacillus salivarius LS01 (DSM 22775) and Bifidobacterium breve B632 (DSM 24706) mixture could reduce asthma exacerbations in children, followed in a primary care setting.Methods: The study was randomized, placebo-controlled, and double-blind. It involved 11 Italian primary care pediatricians. The probiotic mixture (containing Ligilactobacillus salivarius LS01 1 × 109 live cells and Bifidobacterium breve B632 1 × 109 live cells) or placebo was taken twice daily (1 sachet in the morning and 1 in the evening) for eight weeks and subsequently once daily for a further eight weeks. Outcomes included number, severity, and duration of asthma exacerbations, intensity of maintenance and as need treatments, and safety.Results: The per-protocol population included 422 children (mean age seven years, 240 males and 182 females). The probiotic mixture significantly reduced the number of asthmatic exacerbations (OR = 3.17). In addition, the number of children with two exacerbations was less than a third in the active group (OR = 3.65).Conclusions: This PROPAM study demonstrated that probiotic strains Ligilactobacillus salivarius LS01 (DSM 22775) and Bifidobacterium breve B632 (DSM 24706) were safe and significantly reduced by more than a third the frequency of asthma exacerbations. At present, the first-line treatment of asthma is still drug-based, but specific strains of probiotics may be auxiliary remedies. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
36. Bifidobacteria Strain Typing by Fourier Transform Infrared Spectroscopy.
- Author
-
Deidda, Francesca, Bozzi Cionci, Nicole, Cordovana, Miriam, Campedelli, Ilenia, Fracchetti, Fabio, Di Gioia, Diana, Ambretti, Simone, and Pane, Marco
- Subjects
FOURIER transform infrared spectroscopy ,BIFIDOBACTERIUM ,TIME-of-flight mass spectrometry ,PULSED-field gel electrophoresis ,BIFIDOBACTERIUM longum ,INFRARED absorption ,PHENOTYPIC plasticity - Abstract
Fourier transform infrared (FTIR) spectroscopy, a technology traditionally used in chemistry to determine the molecular composition of a wide range of sample types, has gained growing interest in microbial typing. It is based on the different vibrational modes of the covalent bonds between atoms of a given sample, as bacterial cells, induced by the absorption of infrared radiation. This technique has been largely used for the study of pathogenic species, especially in the clinical field, and has been proposed also for the typing at different subspecies levels. The high throughput, speed, low cost, and simplicity make FTIR spectroscopy an attractive technique also for industrial applications, in particular, for probiotics. The aim of this study was to compare FTIR spectroscopy with established genotyping methods, pulsed-field gel electrophoresis (PFGE), whole-genome sequencing (WGS), and multilocus sequence typing (MLST), in order to highlight the FTIR spectroscopy potential discriminatory power at strain level. Our study focused on bifidobacteria, an important group of intestinal commensals generally recognized as probiotics. For their properties in promoting and maintaining health, bifidobacteria are largely marketed by the pharmaceutical, food, and dairy industries. Strains belonging to Bifidobacterium longum subsp. longum and Bifidobacterium animalis subsp. lactis were taken into consideration together with some additional type strains. For B. longum subsp. longum , it was possible to discriminate the strains with all the methods used. Although two isolates were shown to be strictly phylogenetically related, constituting a unique cluster, based on PFGE, WGS, and MLST, no clustering was observed with FTIR. For B. animalis subsp. lactis group, PFGE, WGS, and MLST were non-discriminatory, and only one strain was easily distinguished. On the other hand, FTIR discriminated all the isolates one by one, and no clustering was observed. According to these results, FTIR analysis is not only equivalent to PFGE, WGS, and MLST, but also for some strains, in particular, for B. animalis subsp. lactis group, more informative, being able to differentiate strains not discernible with the other two methods based on phenotypic variations likely deriving from certain genetic changes. Fourier transform infrared spectroscopy has highlighted the possibility of using the cell surface as a kind of barcode making tracing strains possible, representing an important aspect in probiotic applications. Furthermore, this work constitutes the first investigation on bifidobacterial strain typing using FTIR spectroscopy. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
37. Improving and Comparing Probiotic Plate Count Methods by Analytical Procedure Lifecycle Management.
- Author
-
Weitzel, M. L. Jane, Vegge, Christina S., Pane, Marco, Goldman, Virginia S., Koshy, Binu, Porsby, Cisse Hedegaard, Burguière, Pierre, and Schoeni, Jean L.
- Subjects
PROBIOTICS ,BACTERIAL inactivation ,CELL determination ,DECISION making ,MICROBIOLOGY ,UNCERTAINTY - Abstract
Probiotics are live microorganisms that confer a health benefit to the host when administered in adequate amounts. This definition links probiotic efficacy to microbial viability. The current gold standard assay for probiotic potency is enumeration using classical microbiology plating-based procedures, yielding results in colony-forming units (CFU). One drawback to plating-based procedures is high variability due to intrinsic and extrinsic uncertainties. These uncertainties make comparison between analytical procedures challenging. In this article, we provide tools to reduce measurement uncertainty and strengthen the reliability of probiotic enumerations by using analytical procedure lifecycle management (APLM). APLM is a tool that uses a step-by-step process to define procedure performance based on the concept that the reportable value (final CFU result) must be fit for its intended use. Once the procedure performance is defined, the information gathered through APLM can be used to evaluate and compare procedures. Here, we discuss the theory behind applying APLM and give practical information about its application to CFU enumeration procedures for probiotics using a simulated example and data set. Data collected in a manufacturer's development laboratory is included to support application of the concept. Implementation of APLM can lead to reduced variability by identifying specific factors (e.g., the dilution step) with significant impact on the variability and providing insights to procedural modifications that lead to process improvement. Understanding and control of the analytical procedure is improved by using these tools. The probiotics industry can confidently apply the information and analytical results generated to make decisions about processes and formulation, including overage requirements. One benefit of this approach is that companies can reduce overage costs. More reliable procedures for viable cell count determinations will improve the quality evaluation of probiotic products, and hence manufacturing procedures, while ensuring that products deliver clinically demonstrated beneficial doses. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
38. Supplementation with Bifidobacterium breve BR03 and B632 strains improved insulin sensitivity in children and adolescents with obesity in a cross-over, randomized double-blind placebo-controlled trial.
- Author
-
Solito, Arianna, Bozzi Cionci, Nicole, Calgaro, Matteo, Caputo, Marina, Vannini, Lucia, Hasballa, Iderina, Archero, Francesca, Giglione, Enza, Ricotti, Roberta, Walker, Gillian Elisabeth, Petri, Antonella, Agosti, Emanuela, Bellomo, Giorgio, Aimaretti, Gianluca, Bona, Gianni, Bellone, Simonetta, Amoruso, Angela, Pane, Marco, Di Gioia, Diana, and Vitulo, Nicola
- Abstract
Variations in gut microbiota might impact metabolism leading to body weight excess. We assessed the impact of a probiotic supplementation in pediatric obesity on weight, metabolic alterations, selected gut microbial groups, and functionality. Cross-over, double-blind, randomized control trial (BIFI-OBESE trial; NCT03261466). 101 youths (6–18 years, Tanner stage ≥2) with obesity and insulin-resistance on diet were randomized to 2 × 10
9 CFU/AFU/day of Bifidobacterium breve BR03 (DSM 16604) and B. breve B632 (DSM 24706) (51) or placebo (50) for 8 weeks with a 4-weeks wash-out period. All subjects (M/F 54/47) completed the first 8 weeks, and 82 (M/F 43/39) the last part without adverse events. Mixed-effects models revealed a carry-over effect on many variables in the entire study, narrowing the analysis to the first 8 weeks before the wash-out periods. All subjects improved metabolic parameters, and decreased weight and Escherichia coli counts. Probiotics improved insulin sensitivity at fasting (QUICKI, 0.013 CI95%0.0–0.03) and during OGTT (ISI, 0.654 CI95%-0.11–1.41). Cytokines, GLP1, and target microbial counts did not vary. Of 25 SCFAs, acetic acid and acetic acid pentyl-ester relative abundance remained stable in the probiotics, while increased in the placebo (p < 0.02). A signature of five butanoic esters identified three clusters, one of them had better glucose responses during probiotics. An 8 weeks treatment with B. breve BR03 and B632 had beneficial effects on insulin sensitivity in youths with obesity. Microbiota functionality could influence metabolic answers to probiotics. Long-term studies to confirm and enrich our findings are justified. Tailored probiotic treatments could be an additional strategy for obesity. NCT03261466. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
39. The PRObiotics in Pediatric Asthma Management (PROPAM) study: A post hoc analysis in preschoolers.
- Author
-
Ciprandi, Giorgio, Cioffi, Luigi, Giuliano, Maria, Pane, Marco, and Drago, Lorenzo
- Published
- 2022
- Full Text
- View/download PDF
40. Probiotics May Have Beneficial Effects in Parkinson's Disease: In vitro Evidence.
- Author
-
Magistrelli, Luca, Amoruso, Angela, Mogna, Luca, Graziano, Teresa, Cantello, Roberto, Pane, Marco, and Comi, Cristoforo
- Subjects
PARKINSON'S disease ,KLEBSIELLA pneumoniae ,CYTOKINES ,ESCHERICHIA coli ,OXIDATIVE stress - Abstract
Background: Parkinson's disease (PD) is characterized by loss of dopaminergic neurons and intraneuronal accumulation of alpha-synuclein, both in the basal ganglia and in peripheral sites, such as the gut. Peripheral immune activation and reactive oxygen species (ROS) production are important pathogenetic features of PD. In this context, the present study focused on the assessment of in vitro effects of probiotic bacterial strains in PBMCs isolated from PD patients vs. healthy controls. Methods: 40 PD patients and 40 matched controls have been enrolled. Peripheral blood mononuclear cells (PBMCs) were isolated and co-cultured with a selection of probiotics microorganisms belonging to the lactobacillus and bifidobacterium genus. In vitro release of the major pro- (Tumor Necrosis Factor-alpha and Interleukin-17A and 6) and anti-inflammatory (Interleukin 4 and 10) cytokines by PBMCs, as well as the production of ROS was investigated. Furthermore, we assessed the ability of probiotics to influence membrane integrity, antagonize the growth of potential pathogen bacteria, such as Escherichia coli and Klebsiella pneumoniae and encode tyrosine decarboxylase genes (tdc). Results: All probiotic strains were able to inhibit inflammatory cytokines and ROS production in both patients and controls. The most striking results were obtained in PD subjects with L. salivarius LS01 and L. acidophilus which significantly reduced pro-inflammatory and increased the anti-inflammatory cytokines (p < 0.05). Furthermore, most strains determined restoration of membrane integrity and inhibition of E. coli and K. pneumoniae. Finally, we also showed that all the strains do not carry tdc gene, which is known to decrease levodopa bioavailability in PD patients under treatment. Conclusions: Probiotics exert promising in vitro results in decreasing pro-inflammatory cytokines, oxidative stress and potentially pathogenic bacterial overgrowth. In vivo longitudinal data are mandatory to support the use of bacteriotherapy in PD. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
41. Improving End-User Trust in the Quality of Commercial Probiotic Products.
- Author
-
Jackson, Scott A., Schoeni, Jean L., Vegge, Christina, Pane, Marco, Stahl, Buffy, Bradley, Michael, Goldman, Virginia S., Burguière, Pierre, Atwater, John B., and Sanders, Mary Ellen
- Subjects
COMMERCIAL products ,PROBIOTICS ,COMMERCIAL trusts ,MICROBIAL products ,ECO-labeling ,LABELS ,SCIENTIFIC method ,U.S. states - Abstract
In a rapidly growing global probiotic market, end-users have difficulty distinguishing between high quality and poor quality products. This ambiguity threatens the trust consumers and healthcare providers have in probiotic products. To address this problem, we recommend that companies undergo third-party evaluations to certify probiotic quality and label accuracy. In order to communicate about product quality to end-users, indication of certification on product labels is helpful, although not all manufacturers choose to use this approach. Herein we discuss: third-party certification, the process of setting standards for identity, purity, and quantification of probiotics; some emerging methodologies useful for quality assessment; and some technical challenges unique to managing quality of live microbial products. This review provides insights of an Expert Panel engaged in this process and aims to update the reader on relevant current scientific methodologies. Establishing validated methodologies for all aspects of quality assessment is an essential component of this process and can be facilitated by established organizations, such as United States Pharmacopeia. Emerging methodologies including whole genome sequencing and flow cytometry are poised to play important roles in these processes. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
42. Effects of Probiotics on Cognitive Reactivity, Mood, and Sleep Quality.
- Author
-
Marotta, Angela, Sarno, Eleonora, Del Casale, Antonio, Pane, Marco, Mogna, Luca, Amoruso, Angela, Felis, Giovanna E., and Fiorio, Mirta
- Subjects
PROBIOTICS ,COGNITIVE ability ,MOOD (Psychology) ,BIFIDOBACTERIUM longum ,FATIGUE (Physiology) - Abstract
Recent demonstration that probiotics administration has positive effects on mood state in healthy populations suggests its possible role as an adjunctive therapy for depression in clinical populations and as a non-invasive strategy to prevent depressive mood state in healthy individuals. The present study extends current knowledge on the beneficial effects of probiotics on psychological well-being, as measured by changes in mood (e.g., cognitive reactivity to sad mood, depression, and anxiety), personality dimensions, and quality of sleep, which have been considered as related to mood. For this double-blind, placebo-controlled study 38 healthy volunteers assigned to an experimental or control group assumed a daily dose of a probiotic mixture (containing Lactobacillus fermentum LF16, L. rhamnosus LR06, L. plantarum LP01, and Bifidobacterium longum BL04) or placebo, respectively, for 6 weeks. Mood, personality dimensions, and sleep quality were assessed four times (before the beginning of the study, at 3 and 6 weeks, and at 3 weeks of washout). A significant improvement in mood was observed in the experimental group, with a reduction in depressive mood state, anger, and fatigue, and an improvement in sleep quality. No between-groups differences were found. These findings corroborate the positive effect of probiotics on mood state and suggest that probiotics administration may improve psychological well-being by ameliorating aspects of mood and sleep quality. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
43. The In Vitro Effectiveness of Lactobacillus fermentum Against Different Candida Species Compared With Broadly Used Azoles.
- Author
-
Deidda, Francesca, Amoruso, Angela, Nicola, Stefania, Graziano, Teresa, Pane, Marco, Allesina, Serena, Raiteri, Elisabetta, Del Piano, Mario, and Mogna, Luca
- Published
- 2016
- Full Text
- View/download PDF
44. The Possible Innovative Use of Bifidobacterium longum W11 in Association With Rifaximin.
- Author
-
Graziano, Teresa, Amoruso, Angela, Nicola, Stefania, Deidda, Francesca, Allesina, Serena, Pane, Marco, Piffanelli, Pietro, Strozzi, Francesco, Mogna, Luca, and Del Piano, Mario
- Published
- 2016
- Full Text
- View/download PDF
45. Can Probiotics Reduce Diarrhea and Infant Mortality in Africa?
- Author
-
Del Piano, Mario, Coggiola, Francesco, Pane, Marco, Amoruso, Angela, Nicola, Stefania, and Mogna, Luca
- Published
- 2016
- Full Text
- View/download PDF
46. Searching for the Perfect Homeostasis.
- Author
-
Nicola, Stefania, Amoruso, Angela, Deidda, Francesca, Pane, Marco, Allesina, Serena, Mogna, Luca, Del Piano, Mario, and Mogna, Giovanni
- Published
- 2016
- Full Text
- View/download PDF
47. Probiotic Streptococcus thermophilus FP4 and Bifidobacterium breve BR03 Supplementation Attenuates Performance and Range-of-Motion Decrements Following Muscle Damaging Exercise.
- Author
-
Jäger, Ralf, Purpura, Martin, Stone, Jason D., Turner, Stephanie M., Anzalone, Anthony J., Eimerbrink, Micah J., Pane, Marco, Amoruso, Angela, Rowlands, David S., and Oliver, Jonathan M.
- Abstract
Probiotics have immunomodulatory effects. However, little is known about the potential benefit of probiotics on the inflammation subsequent to strenuous exercise. In a double-blind, randomized, placebo controlled, crossover design separated by a 21-day washout, 15 healthy resistance-trained men ingested an encapsulated probiotic Streptococcus (S.) thermophilus FP4 and Bifidobacterium (B.) breve BR03 at 5 bn live cells (AFU) concentration each, or a placebo, daily for 3 weeks prior to muscle-damaging exercise (ClinicalTrials.gov NCT02520583). Isometric strength, muscle soreness, range of motion and girth, and blood interleukin-6 (IL-6) and creatine kinase (CK) concentrations were measured from pre- to 72 h post-exercise. Statistical analysis was via mixed models and magnitude-based inference to the standardized difference. Probiotic supplementation resulted in an overall decrease in circulating IL-6, which was sustained to 48 h post-exercise. In addition, probiotic supplementation likely enhanced isometric average peak torque production at 24 to 72 h into the recovery period following exercise (probiotic--placebo point effect ±90% CI: 24 h, 11% ± 7%; 48 h, 12% ± 18%; 72 h, 8% ± 8%). Probiotics also likely moderately increased resting arm angle at 24 h (2.4% ± 2.0%) and 48 h (1.9% ± 1.9%) following exercise, but effects on soreness and flexed arm angle and CK were unclear. These data suggest that dietary supplementation with probiotic strains S. thermophilus FP4 and B. breve BR03 attenuates performance decrements and muscle tension in the days following muscle-damaging exercise. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
48. In Vitro Activity of Lactobacillus fermentum LF5 Against Different Candida Species and Gardnerella vaginalis.
- Author
-
Deidda, Francesca, Amoruso, Angela, Allesina, Serena, Pane, Marco, Graziano, Teresa, Del Piano, Mario, and Mogna, Luca
- Published
- 2016
- Full Text
- View/download PDF
49. Assessing Gut Microbiota in an Infant with Congenital Propionic Acidemia before and after Probiotic Supplementation.
- Author
-
Bordugo, Andrea, Salvetti, Elisa, Rodella, Giulia, Piazza, Michele, Dianin, Alice, Amoruso, Angela, Piacentini, Giorgio, Pane, Marco, Torriani, Sandra, Vitulo, Nicola, and Felis, Giovanna E.
- Subjects
GUT microbiome ,PROBIOTICS ,ACIDOSIS ,BACTEROIDES fragilis ,LOW-protein diet ,INFANTS ,DIETARY supplements - Abstract
Propionic Acidemia (PA) is a rare inherited metabolic disorder caused by the enzymatic block of propionyl-CoA carboxylase with the consequent accumulation of propionic acid, which is toxic for the brain and cardiac cells. Since a considerable amount of propionate is produced by intestinal bacteria, interest arose in the attempt to reduce propionate-producing bacteria through a monthly antibiotic treatment of metronidazole. In the present study, we investigated the gut microbiota structure of an infant diagnosed at 4 days of life through Expanded Newborn Screening (NBS) and treated the child following international guidelines with a special low-protein diet, specific medications and strict biochemical monitoring. Microbiota composition was assessed during the first month of life, and the presence of Bacteroides fragilis, known to be associated with propionate production, was effectively decreased by metronidazole treatment. After five antibiotic therapy cycles, at 4 months of age, the infant was supplemented with a daily mixture of three bifidobacterial strains, known not to be propionate producers. The supplementation increased the population of bifidobacteria, with Bifidobacterium breve as the dominating species; Ruminococcus gnavus, an acetate and formate producer, was also identified. Metabarcoding analysis, compared with low coverage whole metagenome sequencing, proved to capture all the microbial biodiversity and could be the elected tool for fast and cost-effective monitoring protocols to be implemented in the follow up of rare metabolic disorders such as PA. Data obtained could be a possible starting point to set up tailored microbiota modification treatment studies in the attempt to improve the quality of life of people affected by propionic acidemia. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
50. Delivery of Metabolically Neuroactive Probiotics to the Human Gut.
- Author
-
Bron, Peter A., Catalayud, Marta, Marzorati, Massimo, Pane, Marco, Kartal, Ece, Dhir, Raja, and Reid, Gregor
- Subjects
VITAMIN B12 ,SMALL intestine ,HUMAN microbiota ,GASTROINTESTINAL system ,PROBIOTICS ,ANXIETY ,METABOLOMICS - Abstract
The human microbiome is a rich factory for metabolite production and emerging data has led to the concept that orally administered microbial strains can synthesize metabolites with neuroactive potential. Recent research from ex vivo and murine models suggests translational potential for microbes to regulate anxiety and depression through the gut-brain axis. However, so far, less emphasis has been placed on the selection of specific microbial strains known to produce the required key metabolites and the formulation in which microbial compositions are delivered to the gut. Here, we describe a double-capsule technology to deliver high numbers of metabolically active cells derived from the 24-strain probiotic product SH-DS01 to the gastrointestinal tract, including the small intestine, where immune responses and adsorption of metabolites into the bloodstream occur. Based on its genome sequence, Limosilactobacillus reuteri SD-LRE2-IT was predicted to have the genetic capacity to de novo produce a specific metabolite of interest to brain health, vitamin B12, which could be confirmed in vitro. Taken together, our data conceptualizes the importance of rationally defined microbial strain characterization based on genomics and metabolomics data, combined with carefully designed capsule technology for delivery of live cells and concomitant functionality in and beyond the gut ecosystem. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.